Genentech, Inc.

氨基观察-创新药组原创出品 作者 | 郑晓 Biotech-Biopharma-Bigpharma，三部曲的发展应该是所有创新药企的终极梦想。但在20年前，这注定只能是一个梦想。 从研发到上市后的商业化，条条道路艰险，没有人能够轻易跨越。所以，授权合作甚至卖身，是绝大部分biotech的归宿。 在这一逻辑下，美国的生物制药产业，形成了明确的分工合作，biotech主要负责研发，big pharma则依靠买买买，推进后端临床和商业化。 20年后的今天，这一趋势可能在发生变化。 2018年至2023年期间，大约40%的创新药是由几乎没有商业化经验的公司推出的，呈现翻倍增长的趋势。 即便是资本寒冬，这一趋势仍在继续。2024年，FDA获批的48款新药中，5款是没有商业化经验的biotech推动的。实际上，这一数字，可能并不能充分反应biotech的独立意愿。 2024年，全球制药产业并购有所降温，尤其是大型并购接近匿迹：最大的并购案例，只有49亿美元。这背后，很核心的一个原因就是：小型生物技术公司越来越多青睐独立，选择自行将药物推向市场。这意味着，可供大药企购买的后期资产选择更少了。 看起来，更多有鸿鹄之志的biotech，或许会让全球制药产业的生态格局，发生天翻覆地的变化。 / 01 / Biotech的原力觉醒 Biotech的历史，要追逐到上世纪80年代，以基因泰克为代表的药企们，让尚未有收入来源的生物科技公司，受到了市场的认可，“biotech”也由此成为制药产业的重要分支。 但是，2009年基因泰克被罗氏收购，预示了不再以独立的上市公司出现，反应了biotech独立的难度之大。 确实，制药产业冗长复杂，不仅对研发速度有要求，更考验临床研究、临床数据分析和申报注册、商业化等多个环节，每个环节都事关成败。 天下武功唯快不破。任何一个环节拖沓，都足以改变一款药、甚至一家公司的预期。而容易“拖沓”也正是biotech的特点。因为资金、资源层面的天然劣势，导致biotech在前端研发有优势，但到了临床转化环节，可能就会被大药企远远甩下。 这也是为什么，美国的生物制药产业，形成了明确的分工合作，biotech负责研发，大药厂负责转化。在2023年第四季度的电话会议上，强生曾直言，他们布局了50多个较小的交易，因为可以利用“临床开发实力、制造能力和商业影响力”来创造更多价值。 在这样的产业生态下，完成新药首发上市的biotech凤毛麟角。2000年-2011年，首发上市的新药中，只有10%是由没有商业化经验的公司推出。 但正如上文所说，在过去十年左右的时间里，这种模式发生了剧烈的变化。2018年-2023年，高达30%的管线是由小公司自己推出。 并且，目前这一趋势仍然在延续。那么，是哪些因素，使得biotech原力觉醒了呢？ / 02 / 有利因素的融合共振 目前来看，这是由多个有利因素外溢共振的结果。 首先，是产业人才的外溢。过去20年，并购是制药产业最常见的动作。并购，也使得越来越多的人才（包括经验丰富的商业领袖）大量外流到小公司，这增强了这些小公司自创的信心。 生物制药生态的逐步成熟，也导致高精尖人才的稀缺属性在下降。由此，涌现出越来越合格甚至优秀的员工，也增强了biotech自主发展的信心。例如，在美国，加利福尼亚和马萨诸塞州的研发中心，经验丰富的商业和研究人才的来源，使得该地区2000 年至2020年间自主商业化的biotech多达31家，占总数量的比重超过三分之一。 其次，供应链的外溢。如今的小型药企不仅有更多的机会获得人才，而且有更多的选择来购买关键的能力，包括制造、销售、患者服务和药物警戒等职能部门提供专业支持。没错，整个生态圈的完善，也就是CXO的兴起，让biotech可以更大程度上，避免依赖大药企。 尤其是在临床需求稀缺的细分市场中，对疾病领域的深入了解，比投资于大型商业组织的能力更重要。使用供应商可以让首次启动者将其资产商业化，而无需在他们可能缺乏必要的投资能力时建立大型组织。 另外，资本的外溢。目前，海外投资创新药的资金规模已经非常庞大，加上在过去五年的大部分时间里，小型制药公司发现筹集资金相对容易。例如，在后期交易中，2018 年达到40亿美元。目前，虽然资本寒冬，但是市场对于后期资产的热度仍然保持，过去2年IPO主要是后期资产的biotech贡献。 正是这一系列有利因素，导致越来越多biotech的觉醒。未来，这一趋势有可能加深，答案是AI技术的发展。 任何时候，药物发现都是一项复杂且耗时的工程，期间伴随着周而复始的实验、甚至失败。而AI技术的发展，可能缩短这一周期。因此，有海外观点认为，AI通过降低成本的方式，也让更多的biotech有了独自向前的勇气。 / 03 / 商业化仍是“硬伤” 独立最大的好处，自然是创造无限可能。元老级玩家Genmab，在尝遍license out带来的甜蜜与苦楚之后，也不想再为大药企打工了。 Genmab手握多个抗体平台，接连产出了达雷妥尤单抗、奥法木单抗超级重磅炸弹，及amivantamab、teclistamab等其余6个重磅产品。 虽然研发出了百亿美元级的产品，但由于核心权益并未在自己手中，导致可预见的营收天花板，极大限制了公司的想象力。 在市场眼中，如果达雷妥尤单抗等任何一款管线的核心权益在Genmab手中，市值千亿美金不是梦。而目前，其市值只有130亿美元。 有技术、产品，以及一定的商业化经验、资金储备，让Genmab也走上了独立之路。 但比起Genmab，绝大部分biotech的商业化仍是独立路上的硬伤。 麦肯锡数据显示，在过去五年中，只有20%到30%的biotech首发管线上市后，超出了预期；而老牌公司的这一比例为40%到50%。 同样，这些公司中只有10%到20%的表现优于标准普尔生物技术指数，最终还会有10%到20%的公司被收购。这些药企，可能能够给患者带来更好的选择，但在给股东创造价值层面，仍然是不及格的。 可以理解，大药企的商业化能力并不容易颠覆。毕竟，商业化能力、资源，会随着时间的推移，逐步深化。 无论如何，当越来越多的Biotech发起独立宣言，仍然意味着制药产业的生态有可能发生变化。至少，顶级巨头们的阶级，不再再像过去那样固化。 从资本市场的表现来看，确实有部分药企能够实现逆袭。例如，只有一款FcRn抗体获批的argenx，最新市值接近400亿美金。这背后，是由其突出的商业化成绩造就的。 2024年，作为其商业化的第三年，销售额就有可能冲击20亿美元。前三季度，argenx收入规模已经达到14.52亿美元。 今年拿到MASH市场首张入场券的Madrigal，商业化表现也接连超出市场预期，市值逐步上涨。 当综合环境让biotech的逆袭更有利，那么，更多逆袭者的出现，就只是时间问题了。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。

DUBLIN--( BUSINESS WIRE )--The "AI Driven Drug Discovery Patent Landscape Report 2024" report has been added to ResearchAndMarkets.com's offering. The AI-driven drug discovery report provides a detailed patent landscape analysis, reviewing 1,087 patents from a range of primary jurisdictions, with data from both patent filings and market sales insights. It combines quantitative and qualitative data, offering a reliable data foundation that includes patent applications, technology trends, and market sales growth rates. This multifaceted approach enables a thorough understanding of the current market position, potential growth areas, and emerging technological advancements in AI-driven drug discovery. The report is divided into key sections, each providing insights into critical aspects of the AI-driven drug discovery industry. The primary sections include the Landscape Overview, Market Analysis, Technology Analysis, and Top Player Analysis, each of which contributes a unique perspective to support strategic decisions in R&D, investment, and competitive positioning. Landscape Overview The landscape overview provides a comprehensive snapshot of the patent landscape within AI-driven drug discovery, tracking patent activity from 2002 to 2024. A clear upward trend in patent filings is observed, with a substantial increase in recent years, indicating accelerated innovation and investment in this field. The United States leads with the highest number of patents, followed by China and Europe, emphasizing the global focus and cross-regional competition. The overview section also covers trends in patent ownership, highlighting both established players and emerging entities, which suggests a competitive and evolving field with new entrants continually contributing to AI-driven drug discovery. Market Analysis Section The market analysis section delves into the commercial side of AI-driven drug discovery, focusing on market sales data and projected growth rates. By examining patenting activity alongside market sales data, this section reveals the alignment between technological innovation and market demand. The analysis highlights the market's current trajectory and offers insights into potential growth opportunities, emphasizing regions with significant R&D investment. The report's market analysis sheds light on key areas where AI-driven drug discovery is poised for expansion, helping stakeholders understand both current market dynamics and areas with the highest commercial potential. Technology Analysis Section In the technology analysis section, the report reviews core technological domains within AI-driven drug discovery, such as ICT applications for bioinformatics, machine learning for drug development, and biological computing models. Each technology domain is evaluated for its role in advancing drug discovery methods, such as molecule targeting, pattern recognition, and efficacy testing. This section identifies leading-edge technologies driving innovation and highlights areas with high patenting activity, signaling where future R&D efforts may concentrate. By examining these specific domains, the technology analysis section equips stakeholders with insights into the technical underpinnings that are shaping the future of AI-driven drug discovery. Top Player Section The top player section offers a closer look at the leading organizations and institutions in the field, such as the University of California, Peptilogics, Genentech, MIT, and Harvard University. Each top player is reviewed based on their patent contributions, strategic focus, and technological developments within AI-driven drug discovery. For example, Peptilogics stands out with its NautilusT AI platform for peptide therapeutics, while Genentech is highlighted for its collaboration with NVIDIA, integrating AI for enhanced molecular design. This section also explores collaborations and partnerships among these players, showcasing how strategic alliances are accelerating technological advancements and expanding the scope of AI applications in drug discovery. The report provides a holistic view of AI-driven drug discovery, from market trends and technological innovations to competitive dynamics. Each section complements the others to create a cohesive narrative on the state and direction of the AI-driven drug discovery industry, making it a valuable resource for decision-makers in R&D, policy, and investment. By integrating patent data, market insights, and a close examination of technology and top players, this report serves as a robust guide for stakeholders aiming to understand and capitalize on this rapidly evolving field. What You Will Get: 90+ Pages PDF Report 40+ Pages PDF Slides Excel File of each figure including extended data Key Topics Covered: 1. Key Findings 1.1 Executive Summary 1.2 Introduction 2. Patent Landscape Overview 2.1. Patent Family Analysis 2.2. Patent-Market Coverage 2.3. Geographical Jurisdiction 3. Market and Competitor Analysis 3.1. Market at a Glance 3.2. Market Share of Main Players 3.3. Main Products in AI-Driven Drug Discovery 3.4. Top Applicants 3.5. Market Coverage of Top Applicants 3.6. Top Owners 3.7. Highly-Cited Applicants 3.8. Collaboration 3.8.1. Top Ten Applicants' Collaborations 3.8.2. The Strongest Cooperation Networks 3.9. Top Applicant Activity 3.10. Pioneer Companies in the Last 5 Years 3.11. Top Applicant Clustering 3.12. Pending Patents 4. Technology Analysis 4.1. Top Technologies 4.1.1. Top Technologies by Class 4.1.2. Top Technologies by Sub-Class 4.1.3. Top Technologies by Main-Group 4.1.4. Top Technologies by Sub-Group 4.1.5. Top Technologies and Main Trends 4.2. Five Recent Dominant Technologies 4.3. Key Patents 4.4. Main Themes of Patents 4.5. Technology Clustering 4.6. Top Inventors 5. Key Players' Patent Profile 5.1. California University 5.2. Peptilogics Inc 5.3. Genentech Inc 5.4. Massachusetts Institute of Technology 5.5. Harvard College Companies mentioned in the report include: Peptilogics Inc. University of California Genentech Inc. Insilico Medicine Exscientia BenevolentAI Schrodinger, Inc. Atomwise Microsoft Corporation (Healthcare & Life Sciences) NVIDIA Corporation Z Advanced Computing Inc. University of Miami RowAnalytics Ltd. HeartFlow Inc. Ginkgo Bioworks Reverie Labs Accutar Biotechnology Evommune Novoheart Ltd. Chan Zuckerberg Biohub Inc. Unity Health Toronto EpiAxis Therapeutics Orion Biotechnology Hoffmann-La Roche Berenberg Daniel Watkins Andrew Martin New York University Jecure Therapeutics Seragon Pharmaceuticals Tanox Inc. Products/services mentioned in the report include: NautilusT AI Platform Centaur Chemist Pharma.AI SPARROW Algorithm GRAIL AI Platform AtomNet technology For more information about this report visit https://www.researchandmarkets.com/r/867dqs About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

VANCOUVER, British Columbia & SEATTLE--( BUSINESS WIRE )--Borealis Biosciences, a next-generation RNA medicines company, today announced the appointment of Christian Hordo as CEO; a $30 million infusion from an extension of the Series A led by Westlake BioPartners; and the addition of three new board directors, David Allison, Ph.D., Tom Frohlich and Catherine Thut, Ph.D. Borealis was founded on the premise that a convergence of scientific and translational breakthroughs can enable RNA therapeutics to address major unmet needs for patients with kidney diseases. In August, the company emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research collaboration funding from the pharma. With the Series A expansion, the company now has $180 million of capital to advance its programs. “On behalf of the board, I am delighted to welcome Christian as CEO, and to work again with Westlake,” said Jerel Davis Ph.D., managing director at Versant and chairperson of Borealis. “Borealis continues to build momentum in terms of research, new leadership talent, and this recent capital raise.” “I’m honored to lead this world-class team in developing RNA therapies for kidney disease,” said Christian Hordo, who joined as CEO this month. “Borealis is increasingly well-positioned to deliver on the promise of RNAi to make a meaningful impact on the lives of patients and their families. The strength of the team, clarity in strategy, and robust capital position uniquely position Borealis to emerge as a leader in this space.” Mr. Hordo previously was EVP and Chief Business Officer at Sana Biotechnology, where he was a founding executive team member, overseeing multiple strategic and operational functions. Prior to that, he was Head of Business Development and Myeloma Program Lead at Juno Therapeutics. Prior to Juno, Mr. Hordo served in various roles of increasing responsibility at Genentech. He holds an M.B.A. from Harvard Business School, a M.Sc. in Medical Genetics and Microbiology from the University of Toronto, and a B.S. in Psychology from McGill University. “Extending precision medicine to renal disease is an exciting new frontier, and we look forward to working alongside this incredible team and syndicate to develop the next generation of RNA therapeutics for patients,” said David Allison, Ph.D., managing director at Westlake who joined Borealis’ board in connection with the Series A expansion. Also today, Borealis announced two additional board appointments with Mr. Frohlich and Dr. Thut. Mr. Frohlich is CEO of Jade Biosciences. He brings over 20 years of experience in company building, business strategy, and product development. Before Jade, he was COO of Chinook Therapeutics, the predecessor company to Borealis that was acquired by Novartis for $3.2 billion in 2023. Dr. Thut is currently the Therapeutic Area Strategy Head, TAx at Novartis. She possesses nearly 25 years of experience in the pharmaceutical and biotech industries, encompassing a diverse range of roles in research, business development, portfolio strategy, and executive leadership. About Borealis Biosciences Borealis is backed by founding investor Versant Ventures, Novartis and Westlake BioPartners, and has entered into a strategic research collaboration with Novartis. Borealis’ research site is based in Vancouver at the 23,000 square foot operating site formerly leased by Chinook Therapeutics. The facility includes state-of-the-art wet labs for molecular and cellular biology, vivarium space, chemistry and analytical capabilities. The initial 25+ team is made up of experienced drug hunters with extensive expertise in kidney disease, translational systems biology and data sciences, translational biology, chemistry, DMPK and pharmacology.